0000950170-23-065919.txt : 20231122
0000950170-23-065919.hdr.sgml : 20231122
20231122181942
ACCESSION NUMBER: 0000950170-23-065919
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231120
FILED AS OF DATE: 20231122
DATE AS OF CHANGE: 20231122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Encrantz Staffan
CENTRAL INDEX KEY: 0001870875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40587
FILM NUMBER: 231434705
MAIL ADDRESS:
STREET 1: C/O SIGHT SCIENCES, INC.
STREET 2: 4040 CAMPBELL AVENUE, SUITE 100
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sight Sciences, Inc.
CENTRAL INDEX KEY: 0001531177
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 800625749
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 SAND HILL ROAD
STREET 2: BUILDING 3, SUITE 105
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: (415) 889-0550
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD
STREET 2: BUILDING 3, SUITE 105
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2023-11-20
0001531177
Sight Sciences, Inc.
SGHT
0001870875
Encrantz Staffan
C/O SIGHT SCIENCES, INC.
4040 CAMPBELL AVE., SUITE 100
MENLO PARK
CA
94025
true
false
true
false
false
Common Stock
2023-11-20
4
P
false
79234
2.2489
A
236733
D
Common Stock
2023-11-21
4
P
false
68477
2.4758
A
305210
D
Common Stock
2023-11-22
4
P
false
41085
2.4999
A
346295
D
Common Stock
1184258
I
See footnote
Common Stock
4022118
I
See footnote
Reflects the weighted average price at which these shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased. The shares were purchased in multiple transactions at prices ranging from $2.225 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $2.34 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $2.495 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program, which are subject to vesting as previously reported.Each RSU represents a contingent right to receive one share of Common Stock.
These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any.
These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any.
/s/ Jeremy Hayden, Attorney-in-Fact for Staffan Encrantz
2023-11-22